TruScreen Appoints Indonesian Distributor

ZX/ASX Announcement

29 January 2025

TruScreen appoints distributor to Indonesia

• TruScreen appoints PT Mawar Mitra Medika to distribute its AI enabled TruScreen cervical cancer screening system in Indonesia
• Indonesia is the world’s largest Islamic nation with a population of ~283 million
• 37,000 women diagnosed with cervical cancer annually with a 57% mortality rate.**
• Estimate screening population of over 95 million women*.

TruScreen Group Limited (“TrusScreen” or “the Company”) advises the appointment of Indonesian medical products distributor PT Mawar Mitra Medika to distribute its unique AI enabled TruScreen cervical cancer screening system in Indonesia. Indonesia, with a population exceeding 283 million, is the world’s most populous Islamic nation. It has an addressable screening market of 95 million women. It is estimated** that ~37,000 women are diagnosed with and 21,000 die from cervical cancer each year in Indonesia yet only 11% of women have ever been screened for cervical cancer.

With over 14,000 islands in the Indonesian archipelago TruScreen’s portability and its AI enabled technology provides real time results without the needs of expensive laboratory infrastructure, makes it an ideal screening solution for such a geographically distributed population. TruScreen technology is non-invasive and is culturally sensitive to Indonesian patients as it does not require a collection of cervical cells.

The appointment follows the registration of TruScreen by the Indonesian regulator in October 2024. In December 2024, TruScreen CEO, Mr Martin Dillon met with Indonesian Key Opinion Leaders and Ministry of Health Officials to explore the use of AI technology to reduce the unnecessary loss of life from cervical cancer.

TruScreen acknowledges the assistance of Austrade Jakarta, for facilitating the appointment of PT Mawar Mitra Medika.

Mr Dillon was invited to present at the Indonesian AI webinar, subsequent to his participation in a November 2024 WHO meeting, in Edinburgh, to explore the use of AI enabled devices for the screening of cervical cancer.

TruScreen was recognised by WHO, UNITAID and several national organisations including:
• the Chinese Obstetricians and Gynaecologists Association (COGA),
• the Chinese Society for Colposcopy and Cervical Pathology (CSCCP),
• the Vietnam Ministry of Health National Technical List,
• COFEPRIS, the Mexican public health regulator, and
• The Russia Cervical Cancer Screening Guidelines.
TruScreen CEO, Martin Dillon commented:

“This appointment supports two key strategies of TruScreen. The first is to complete a vertical East Asian distribution focus from Indonesia, north through the ASEAN countries, Vietnam and Indo- China and then

China. This regional vertical market is now in place. The second is a focus on Asia’s populous Islamic nations. Our Indonesian distributor complements our distributors in Saudi Arabia, UAE, Kuwait, Jordan and Palestine.”

This announcement has been approved by the Board.

*CIA World Factbook women aged 15-64 = 95,961,293
**ICO/IARC HPV Information Centre (*ICO = Catalan Institute of Oncology and IARC = International Agency for Research on Cancer)

Ends


For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
[email protected]
Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF